A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people with lymphoma have this type, and it mainly affects older adults. It’s a fast ...

Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line ...

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

About a third of patients with diffuse large B ... induces T cell-intrinsic changes via calcium signaling modulation." DLBCL is the most common type of non-Hodgkin lymphoma, affecting more than ...

B-ALL/NHL 2002 protocol achieved a 3-year overall survival and progression-free survival of 73% in adult patients with Burkitt lymphoma/leukemia (BL). While demonstrating efficacy comparable with ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...